These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31748278)

  • 41. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
    Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
    Liu KH; Zhang L; Chen JX; Lian CL; Wang J; He ZY; Wu SG
    Breast; 2020 Feb; 49():233-241. PubMed ID: 31918322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant chemotherapy and survival outcome in node-negative breast cancer with a 21-gene recurrence score of 26-30.
    Yang SP; Yao J; Zhou P; Lian CL; Wang J; Fang MX; Wu SG
    Future Oncol; 2021 Jun; 17(17):2183-2192. PubMed ID: 33605163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
    Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
    Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.
    Kim HJ; Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
    Clin Imaging; 2021 Jul; 75():131-137. PubMed ID: 33548871
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
    Buechler SA; Gökmen-Polar Y; Badve SS
    Clin Breast Cancer; 2019 Feb; 19(1):17-26.e8. PubMed ID: 30097312
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    Roberts MC; Miller DP; Shak S; Petkov VI
    Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of Magee and Oncotype DX Recurrence Scores in estrogen receptor positive breast cancers.
    Walts AE; Mirocha JM; Bose S
    Breast J; 2018 Nov; 24(6):951-956. PubMed ID: 30230113
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prediction of Oncotype Dx recurrence score using clinical parameters: A comparison of available tools and a simple predictor based on grade and progesterone receptor.
    Thibodeau S; Voutsadakis IA
    Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):89-96. PubMed ID: 30796885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
    Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
    Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oncotype DX
    Pease AM; Riba LA; Gruner RA; Tung NM; James TA
    Ann Surg Oncol; 2019 Feb; 26(2):366-371. PubMed ID: 30542840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
    Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The American Joint Commission Cancer 8th Edition Prognostic Stage Including Oncotype DX® Recurrence Score: Impact on Staging of Early Breast Cancer.
    O'Cearbhaill R; Gannon JM; Prichard RS; Walshe JM; McDermott E; Quinn CM
    Pathobiology; 2019; 86(2-3):77-82. PubMed ID: 30347405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer.
    Yang PS; Lee YH; Chung CF; Chang YC; Wang MY; Lo C; Tsai LW; Shih KH; Lei J; Yu BL; Cheng SH; Huang CS
    Jpn J Clin Oncol; 2019 Dec; 49(11):1029-1036. PubMed ID: 31287883
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients.
    Zhu Y; Wang T; Tong Y; Chen X; Shen K
    Front Endocrinol (Lausanne); 2021; 12():725161. PubMed ID: 34456877
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
    Joh JE; Esposito NN; Kiluk JV; Laronga C; Lee MC; Loftus L; Soliman H; Boughey JC; Reynolds C; Lawton TJ; Acs PI; Gordan L; Acs G
    Oncologist; 2011; 16(11):1520-6. PubMed ID: 22016474
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.
    Wu J; Fang Y; Lin L; Fei X; Gao W; Zhu S; Zong Y; Chen X; Huang O; He J; Zhu L; Chen W; Li Y; Shen K
    Oncotarget; 2017 Jun; 8(24):38706-38716. PubMed ID: 28404972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort.
    Grenader T; Yerushalmi R; Tokar M; Fried G; Kaufman B; Peretz T; Geffen DB
    Oncology; 2014; 87(1):1-6. PubMed ID: 24970679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.